SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
Analyst: 3 Key Reasons Why a Gilead-Vertex Marriage May Not be a Match Made in Biotech Heaven
Deals
3 Key Reasons Why a Gilead-Vertex Marriage May Not be a Match Made in Biotech Heaven
July 5, 2017
 · 
3 min read
Deals
Why Vertex Could Still Be Gilead’s Best Takeover Option
June 30, 2017
 · 
1 min read
Biotech Bay
Is Gilead On The Verge Of A Powerful Rally?
June 22, 2017
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Deals
Why This Tiny Massachusetts Biotech Could be a New M&A Target for Drug Giants Like Gilead and Celgene
June 16, 2017
 · 
2 min read
Sources Reveal Tesaro is Unlikely to Find a Buyer
Deals
Gilead, Sanofi Reportedly Bidding on This $10 Billion Massachusetts Biotech
June 13, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
BioMidwest
The Single Best Hep C Drug Stock to Buy in 2017—Hint, It’s Not Gilead
June 9, 2017
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
A Look at Gilead’s Possible New Drug Strategy
May 31, 2017
 · 
3 min read
Biotech Bay
How To Double Your Money On A 6% Up Move In Gilead
May 25, 2017
 · 
1 min read
Biotech Bay
Why Gilead Stock Lagged Behind Other Biotechs In April
May 10, 2017
 · 
1 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Gilead Commits $100M to Tackle the HIV/AIDS Epidem
Business
Gilead Commits $100M to Tackle the HIV/AIDS Epidemic in the Southern U.S.
December 4, 2017
 · 
6 min read
Business
X-Chem and Gilead Announce Drug Discovery Collaboration
November 28, 2017
 · 
3 min read
Business
Gilead Sciences Announces Fourth Quarter 2017 Dividend
October 26, 2017
 · 
1 min read
Drug Development
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy in HBV Patients Switched From Viread
October 20, 2017
 · 
15 min read
Biotech Beach
As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada
October 17, 2017
 · 
5 min read
Business
Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
October 17, 2017
 · 
2 min read
Biotech Bay
Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
October 16, 2017
 · 
3 min read
Business
Gilead To Release Third Quarter 2017 Financial Results On Thursday, October 26, 2017
October 13, 2017
 · 
1 min read
Business
The Medicines Patent Pool And Gilead Sign License For Bictegravir
October 4, 2017
 · 
3 min read
Drug Development
Gilead Presents Results From Phase III Study Evaluating Patients Who Switched To Investigational Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
October 4, 2017
 · 
5 min read
Load More